CD19 and neoplasm: Although CD19 CAR- T cell therapy could reduce CD19-positive tumor burden in R/R t(8;21) AML patients with CD19 aberrant expression, tumor relapses occur rapidly due to CAR-T cell exhaustion or antigen escape.